Investigation of GPR137C as a promising novel marker for the progression of prostate cancer through G4 screen and bioinformatics analyses
This study establishes promoter G4s as epigenetic regulators in PCa while proposing GPR137C as both a prognostic biomarker and a therapeutic nexus for GPCR-targeted drug development.
Authors
- Chuanjun Shu (ORCID: https://orcid.org/0000-0002-1427-2037)
- Saisai Chen (ORCID: https://orcid.org/0000-0002-5718-9102)
- Feng Xu (ORCID: https://orcid.org/0000-0001-6671-328X)
- Hui‐Hu Lu (ORCID: https://orcid.org/0000-0002-2363-962X)
- Xuan Huang (ORCID: https://orcid.org/0000-0002-5346-6029)
- Likai Mao
- Yue Hou (ORCID: https://orcid.org/0000-0002-0806-9083)
Institutions
- Huaian First People’s Hospital (CN)
- Zhongda Hospital Southeast University (CN)
- Jingning County People's Hospital (CN)
- Nanjing Medical University (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-30
- DOI
- https://doi.org/10.3389/fimmu.2025.1576835
- Citations
- 3
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- Government of Jiangsu Province
- Natural Science Foundation of Jiangsu Province
- Fourth Military Medical University